PPA
OCUL icon

Parametric Portfolio Associates’s Ocular Therapeutix OCUL Stock Holding History

Parametric Portfolio Associates’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$139K Buy
28,068
+8,056
+40% +$44.7K ﹤0.01% 3511
2021
Q4 		$139K Buy
20,012
+4,212
+27% +$32.7K ﹤0.01% 3501
2021
Q3 		$158K Sell
15,800
-2,541
-14% -$28.5K ﹤0.01% 3477
2021
Q2 		$260K Buy
18,341
+2,376
+15% +$36.1K ﹤0.01% 3311
2021
Q1 		$262K Sell
15,965
-82,126
-84% -$1.58M ﹤0.01% 3769
2020
Q4 		$2.03M Buy
98,091
+84,789
+637% +$1.26M ﹤0.01% 2640
2020
Q3 		$101K Sell
13,302
-5,495
-29% -$45.6K ﹤0.01% 3794
2020
Q2 		$157K Buy
18,797
+6,034
+47% +$40K ﹤0.01% 3692
2020
Q1 		$63K Buy
12,763
+1,229
+11% +$6.07K ﹤0.01% 3804
2019
Q4 		$46K Sell
11,534
-2,983
-21% -$10.4K ﹤0.01% 3926
2019
Q3 		$44K Buy
14,517
+2,259
+18% +$10.1K ﹤0.01% 3903
2019
Q2 		$54K Sell
12,258
-9,891
-45% -$36.6K ﹤0.01% 3904
2019
Q1 		$88K Buy
22,149
+994
+5% +$4K ﹤0.01% 3832
2018
Q4 		$84K Sell
21,155
-32,613
-61% -$180K ﹤0.01% 3802
2018
Q3 		$370K Sell
53,768
-3,057
-5% -$19.2K ﹤0.01% 3549
2018
Q2 		$384K Sell
56,825
-4,649
-8% -$31.9K ﹤0.01% 3455
2018
Q1 		$400K Buy
61,474
+24,576
+67% +$138K ﹤0.01% 3448
2017
Q4 		$164K Sell
36,898
-13,321
-27% -$68K ﹤0.01% 3783
2017
Q3 		$310K Sell
50,219
-10,300
-17% -$66.3K ﹤0.01% 3662
2017
Q2 		$561K Buy
60,519
+29,937
+98% +$290K ﹤0.01% 3299
2017
Q1 		$284K Buy
30,582
+401
+1% +$3.34K ﹤0.01% 3453
2016
Q4 		$253K Buy
+30,181
New +$234K ﹤0.01% 3505

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Parametric Portfolio Associates's OCUL Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Ocular Therapeutix (OCUL) stake by 40% in Q1 2022, buying an estimated $44.7K and bringing the position to 28,068 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #3511.

Parametric Portfolio Associates first reported a position in OCUL in Q4 2016 and has held it in 22 quarters since. The position peaked at $2.03M in Q4 2020. 133 funds tracked by Wall St. Rank hold OCUL as of Q1 2022.

  • Parametric Portfolio Associates held 28,068 shares of Ocular Therapeutix worth $139K as of Q1 2022.
  • Parametric Portfolio Associates bought 8,056 Ocular Therapeutix shares in Q1 2022, an estimated $44.7K.
  • Ocular Therapeutix made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3511 holding.
  • Parametric Portfolio Associates first reported a position in Ocular Therapeutix in Q4 2016 and has held it in 22 quarters since.
  • Parametric Portfolio Associates's Ocular Therapeutix position peaked at $2.03M in Q4 2020.
  • 133 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.